viral
infect
import
often
unrecogn
compon
diseas
immunocompromis
patient
diagnosi
manag
viral
infect
expand
larg
new
quantit
molecular
diagnost
assay
wellrecogn
pathogen
herp
simplex
viru
hsv
cytomegaloviru
cmv
respiratori
virus
join
newli
recogn
pathogen
bk
viru
human
human
metapneumoviru
highli
suscept
patient
popul
role
epsteinbarr
viru
ebv
human
lymphoprolif
diseas
also
continu
clarifi
result
manag
viral
infect
patient
hematolog
malign
continu
grow
challeng
clinician
herpesvirus
larg
envelop
doublestrand
dna
virus
produc
lifelong
infect
within
host
abil
establish
latenc
make
virus
common
potenti
lifethreaten
challeng
patient
hematolog
malign
undergon
hematopoiet
stem
cell
transplant
hsct
herpesviru
infect
consid
dynam
interact
latent
viru
immun
system
individu
patient
immunocompromis
host
latent
infect
reactiv
lead
invas
diseas
immunemedi
complic
epsteinbarr
viru
ebv
human
malign
eight
known
human
herpesvirus
tradit
divid
three
subfamili
base
genom
organ
homolog
locat
latenc
herp
simplex
virus
type
transmit
intim
mucocutan
contact
includ
oral
mucosa
genitalia
ocular
epithelium
anal
mucosa
respiratori
tract
bloodstream
classic
associ
herp
labiali
infect
oral
mucosa
classic
associ
herp
genitali
infect
genit
tract
common
throughout
unit
state
previou
studi
suggest
mani
healthi
adult
serolog
evid
previou
infect
recent
trend
suggest
overal
decreas
incid
though
may
becom
common
caus
genit
herp
infect
clinic
two
virus
indistinguish
local
reactiv
lead
cutan
herp
lesion
keratoconjunct
distribut
involv
nerv
fiber
dorsal
root
ganglia
viru
remain
latent
loss
cellular
immun
set
hematolog
malign
dissemin
diseas
report
diffus
cutan
erupt
cover
multipl
dermatom
may
occur
may
involv
organ
without
concomit
cutan
lesion
tabl
tonsillar
abscess
format
due
hsv
also
report
patient
histori
chronic
myelogen
leukemia
underw
hsct
patient
chronic
lymphocyt
leukemia
syndrom
gener
lymphadenopathi
attribut
hsv
alon
coinfect
ebv
local
lymphadenopathi
due
hsv
may
seen
individu
oral
genit
infect
may
asymptomat
sever
compromis
host
necrot
spinal
myelopathi
report
patient
tcell
leukemia
confirm
immunohistochem
stain
present
uncommon
cerebrospin
fluid
csf
sampl
sensit
specif
hsv
pcr
csf
thought
close
though
specimen
taken
earli
late
clinic
cours
may
like
fals
neg
brain
biopsi
immunohistochem
stain
remain
definit
hsv
enceph
pcr
unrev
diagnosi
essenti
ocular
diseas
often
made
clinic
examin
though
pcr
cell
scrape
keratoconjunct
vitreou
fluid
case
retin
diseas
may
also
play
role
treatment
consid
patient
activ
hsv
infect
underli
hematolog
malign
hsct
immunocompromis
host
greater
risk
sever
diseas
dissemin
minor
herp
labiali
infect
spread
rapidli
pharynx
esophagu
via
bloodstream
multipl
organ
cutan
dermatom
wide
avail
agent
treatment
hsv
infect
nucleosid
analogu
inhibit
synthesi
hsv
viral
dna
frequent
use
agent
far
acyclovir
though
valacyclovir
famciclovir
vidarabin
foscarnet
use
depend
clinic
scenario
tabl
intraven
therapi
consid
initi
therapi
progress
dissemin
infect
immunocompromis
host
valacyclovir
lvalin
ester
prodrug
acyclovir
absorpt
metabol
acyclovir
liver
prodrug
form
acyclovir
achiev
higher
plasma
level
equival
dose
oral
acyclovir
thu
less
frequent
dose
use
similar
therapeut
level
drug
bid
vs
famciclovir
diacetyl
ester
prodrug
penciclovir
rapidli
convert
bodi
vidarabin
first
antiherpesviru
drug
proven
valu
rare
use
clinic
practic
due
inferior
clinic
trial
acyclovir
signific
toxic
includ
neurotox
parasthesia
ataxia
seizur
rare
coma
foscarnet
direct
noncompetit
inhibitor
herpesviru
dna
polymeras
vitro
activ
herpesvirus
foscarnet
undergo
littl
intracellular
metabol
depend
herpet
thymidin
kinas
requir
phosphoryl
acyclovir
activ
state
therefor
may
use
treatment
acyclovirresist
strain
hsv
aris
due
mutat
viral
thymidin
kinas
util
foscarnet
limit
nephrotox
symptomat
hypocalcemia
electrolyt
magnesium
potassium
loss
requir
coinfus
larg
amount
fluid
except
topic
ocular
antivir
agent
dosag
agent
list
tabl
modifi
set
renal
insuffici
length
therapi
usual
day
except
diseas
involv
cn
wherein
therapi
often
extend
total
day
risk
recurr
acyclovir
resist
foscarnet
gener
use
dose
mgkg
iv
everi
h
day
depend
clinic
respons
patient
hematolog
malign
higher
incid
hsv
shed
saliva
increas
risk
reactiv
hsv
intensifi
immunosuppress
increas
risk
atyp
manifest
dissemin
diseas
set
hsct
hsvseroposit
individu
may
reactiv
rate
thu
routin
implement
prophylaxi
advoc
patient
evid
prior
infect
hsv
seroposit
hematolog
malign
undergo
chemotherapi
hsct
suppress
form
acyclovir
mg
po
bid
higher
valacyclovir
mg
po
qd
bid
famciclovir
mg
po
bid
begin
day
condit
induct
continu
resolut
neutropenia
week
whichev
longer
patient
toler
oral
therapi
iv
acyclovir
mgm
iv
everi
h
also
effect
varicellazost
viru
vzv
third
member
asubfamili
human
herpesvirus
classic
vzv
associ
two
clinic
syndrom
varicella
known
chickenpox
herp
zoster
known
shingl
hsv
patient
underli
lymphoprolif
disord
hsct
higher
risk
dissemin
diseas
system
involv
blur
clinic
entiti
although
frequent
consid
benign
childhood
ill
immunocompet
popul
vzv
carri
overal
case
fatal
rate
death
per
greatest
risk
among
older
adult
infant
older
estim
era
effect
antivir
therapi
zoster
immunoglobulin
put
mortal
children
acut
lymphocyt
leukemia
develop
primari
vzv
compar
hsv
howev
infect
even
ubiquit
peopl
temper
climat
infect
adolesc
infect
typic
spread
via
respiratori
tract
acquisit
primari
infect
physic
contact
mucocutan
lesion
due
great
infect
vzv
attack
rate
high
suscept
host
primari
infect
varicella
present
fever
often
simultan
develop
characterist
cutan
vesicular
rash
involv
mucos
surfac
oropharynx
conjunctiva
genitourinari
tract
etc
begin
small
macular
erythemat
lesion
progress
vesicular
stage
crustingov
day
period
lesion
evolv
differ
time
lesion
may
heal
fresh
lesion
emerg
primari
infect
patient
leukemia
patient
undergon
hsct
occur
often
children
lead
dissemin
involv
multipl
organ
includ
cn
mening
enceph
vascul
intracrani
vessel
immunocompromis
immunolog
host
infect
produc
skin
lesion
persist
longer
period
may
associ
hepat
cholang
pneumon
uveiti
caus
sepsislik
syndrom
dissemin
intravascular
coagul
bacteri
superinfect
skin
lesion
occur
organ
includ
staphylococcu
aureu
lead
cellul
deeper
softtissu
involv
sepsi
often
diagnosi
routin
varicella
zoster
made
base
physic
examin
characterist
rash
distribut
observ
exposur
case
primari
infect
present
differenti
includ
viral
infect
hsv
enterovirus
atyp
present
immunocompromis
host
hsv
tzanck
smear
cell
scrape
cutan
lesion
may
use
lack
sensit
specif
use
specif
molecular
techniqu
common
diagnosi
vzv
tabl
serolog
crossreact
vzv
due
similar
viral
glycoprotein
b
multipl
method
exist
measur
antibodi
vzv
includ
fluoresc
antibodi
membran
antigen
fama
method
enzymelink
immunosorb
assay
eia
latex
agglutin
method
complement
fixat
assay
immunofluoresc
assay
individu
laboratori
may
vari
approach
overal
serolog
test
clinic
use
rapidli
diagnos
vzv
pcr
antigen
detect
case
vzv
immunocompromis
occur
result
viral
reactiv
serolog
test
determin
risk
primari
infect
reliabl
host
though
exact
sensit
specif
pcr
csf
vzv
unclear
pcr
becom
reli
upon
physician
diagnos
cn
infect
due
herpesvirus
gener
vzv
pcr
assay
like
use
earlier
patient
clinic
cours
particularli
primari
infect
suspect
seroconvers
may
delay
pcr
also
use
distinguish
infect
wildtyp
vzv
vaccin
strain
nonimmunocompromis
popul
primari
infect
vzv
selflimit
usual
treat
symptomat
intervent
antivir
therapi
indic
reactiv
diseas
shingl
diffus
diseas
immunocompromis
individu
intraven
acyclovir
mgkg
everi
h
consid
firstlin
therapi
patient
hematolog
malign
hsct
develop
primari
infect
reactiv
vzv
patient
improv
regimen
may
convert
oral
therapi
either
acyclovir
mg
po
valacyclovir
g
po
tid
complet
cours
famciclovir
dose
mg
po
tid
may
also
valu
set
latter
agent
famciclovir
valacyclovir
better
oral
bioavail
acyclovir
expert
recommend
extend
therapi
least
day
beyond
crust
lesion
resist
rare
report
often
patient
underli
hiv
infect
foscarnet
may
altern
agent
resist
develop
medic
requir
dose
reduct
renal
insuffici
patient
hematolog
malign
hsct
regardless
serostatu
avoid
exposur
person
activ
vzv
infect
use
vzv
immunoglobulin
vzig
consid
prevent
infect
seroneg
patient
mean
possibl
reduc
risk
sever
diseas
patient
hematolog
malign
expos
vzv
vaccin
live
vzv
vaccin
consid
advanc
immun
suppress
use
immunocompromis
host
vzvseroneg
patient
administr
vzig
soon
possibl
within
h
exposur
indic
expert
also
report
use
vzig
hsct
patient
signific
exposur
alreadi
known
seroposit
often
hypogammaglobulinem
signific
exposur
includ
contact
individu
chicken
pox
receiv
live
vzv
vaccin
subsequ
develop
varicellalik
rash
risk
transmit
vaccinerel
strain
vzv
dose
vzig
intern
unit
per
kg
bodi
weight
maximum
dose
unit
minimum
dose
unit
given
intramuscularli
administr
h
exposur
unclear
valu
order
prevent
spread
vzv
infect
immunocompromis
individu
vzvseroneg
individu
hospit
set
patient
vzv
diseas
place
airborn
contact
precaut
although
intraven
acyclovir
sever
month
oral
acyclovir
dose
mg
po
bid
year
shown
prevent
vzv
patient
undergo
hsct
longterm
acyclovir
prophylaxi
prevent
vzv
routin
recommend
prevent
immunocompet
individu
use
live
attenu
vzv
vaccin
though
differ
formul
exist
vaccin
use
oka
strain
vzv
isol
healthi
child
varicella
attenu
sequenti
passag
cell
cultur
current
live
vaccin
contraind
use
among
hsct
recipi
immunocompromis
individu
research
need
determin
efficaci
safeti
vzv
vaccin
popul
ideal
howev
healthcar
worker
famili
member
patient
household
contact
vzvseroneg
immun
soon
decis
made
perform
hsct
complet
vaccin
done
week
condit
regimen
begin
inactiv
vaccin
develop
cytomegaloviru
cmv
member
bsubfamili
herpesvirus
infect
unit
state
popul
common
ageadjust
estim
risk
increas
steadili
throughout
individu
lifetim
lower
socioeconom
statu
well
ethnic
background
may
play
role
risk
infect
spread
viru
usual
mucocutan
intim
contact
well
congenit
acquisit
transplant
organ
transfus
blood
product
immunocompromis
patient
popul
coinfect
multipl
strain
report
cmv
one
import
virus
immunocompromis
patient
primari
infect
acquir
hsct
blood
product
reactiv
latent
viru
lead
signific
morbid
primari
infect
cmv
classic
associ
mononucleosislik
syndrom
result
fever
lymphadenopathi
leucopenia
often
rel
lymphocytosi
similar
primari
infect
ebv
case
cmv
frequent
use
heterophil
agglutinin
test
ebv
neg
howev
immunocompromis
patient
patient
underli
inflammatori
disord
cmv
viral
replic
lead
invas
tissu
endorgan
diseas
tabl
virtual
organ
system
affect
invas
cmv
infect
asid
syndrom
list
tabl
cmv
also
blame
caus
hemorrhag
cystiti
patient
hsct
tcell
function
primari
determin
control
cmv
infect
aggress
chemotherapi
use
tcell
deplet
agent
alemtuzumab
increas
risk
cmv
diseas
patient
hematolog
malign
alemtuzumab
particular
associ
rate
cmv
viremia
patient
lymphoprolif
disord
develop
sensit
molecular
techniqu
diagnos
activ
cmv
infect
revolution
approach
cmv
manag
immunosuppress
popul
identifi
patient
risk
requir
preemptiv
prophylact
therapi
becom
promin
approach
hsct
care
particular
quantit
assay
measur
viral
load
blood
impact
manag
infect
tabl
serolog
use
determin
past
exposur
identifi
patient
risk
reactiv
diseas
immunosuppress
neg
patient
may
high
risk
acquir
cmv
infect
transplant
cmv
seroposit
donor
cell
cultur
techniqu
use
human
fibroblast
cell
line
timeconsum
result
day
long
week
order
detect
cytopath
chang
indic
posit
assay
shell
vial
cultur
allow
detect
cmv
antigen
prior
develop
nonexclus
syndrom
cytopath
chang
overal
sensit
specif
limit
frequenc
asymptomat
shed
immunocompromis
host
respiratori
urinari
gastrointestin
site
molecularbas
techniqu
antigenemia
assay
nucleic
acid
amplif
hybrid
captur
assay
commonli
use
diagnosi
activ
cmv
diseas
antigenemia
assay
limit
set
profound
neutropenia
lack
circul
granulocyt
though
exact
predict
valu
test
may
vari
depend
studi
referenc
appear
high
sensit
specif
immunocompromis
patient
patient
undergon
allogen
hsct
pcr
whole
blood
tend
sensit
assay
other
less
specif
plasma
use
molecular
amplif
antigenemia
assay
limit
neutropenia
may
specif
term
predict
activ
diseas
pcr
hybrid
captur
assay
antigenemia
assay
like
use
monitor
patient
respons
therapi
viral
load
may
take
sever
week
becom
undetect
therapi
howev
retest
patient
less
week
initi
treatment
gener
advis
although
nucleosid
analogu
acyclovir
activ
cmv
vitro
relat
purin
analogu
ganciclovir
becom
gold
standard
manag
cmv
diseas
acyclovir
use
prophylaxi
lack
potenc
requir
treatment
establish
cmv
diseas
antivir
clinic
util
treatment
cmv
includ
valganciclovir
prodrug
ganciclovir
foscarnet
cidofovir
latter
two
gener
reserv
infect
caus
ganciclovirresist
strain
cmv
caus
signific
nephrotox
side
effect
agent
less
wellstudi
use
ancillari
agent
may
benefit
certain
clinic
scenario
tabl
valganciclovir
ganciclovir
capabl
induc
hematolog
abnorm
includ
neutropenia
anemia
thrombocytopenia
valganciclovir
lvalyl
ester
prodrug
ganciclovir
greater
bioavail
oral
ganciclovir
mg
dose
valganciclovir
abl
achiev
system
exposur
iv
ganciclovir
dose
mgkg
replac
oral
ganciclovir
clinic
practic
ganciclovir
resist
among
cmv
isol
frequent
due
mutat
phosphatas
ul
gene
less
commonli
dna
polymeras
ul
gene
new
resist
mutat
studi
case
resist
either
document
presum
due
decreas
viral
load
week
therapi
foscarnet
cidofovir
combin
therapi
recommend
antivir
agent
requir
dose
reduct
set
renal
insuffici
foscarnet
cidofovir
may
provok
signific
renal
toxic
although
use
cmvneg
leukocytedeplet
blood
product
help
prevent
cmv
infect
seroneg
patient
risk
never
reduc
zero
prophylaxi
preemptiv
treatment
reduc
signific
morbid
mortal
associ
cmv
diseas
popul
late
cmv
diseas
posthsct
remain
signific
risk
mortal
like
reflect
ongo
immun
dysfunct
ineffect
tcell
control
viral
replic
risk
factor
includ
ongo
pharmacolog
immunosuppress
highdos
corticosteroid
graft
versu
host
diseas
gvhd
need
donor
lymphocyt
infus
previou
cmv
diseas
prophylaxi
iv
ganciclovir
day
posttranspl
effect
prevent
reactiv
cmv
infect
seroposit
hsct
recipi
use
oral
acyclovir
valacyclovir
mani
center
howev
advoc
preemptiv
approach
order
avoid
unnecessari
toxic
prolong
antivir
drug
use
test
blood
atrisk
patient
regular
basi
use
molecular
amplif
antigen
detect
techniqu
often
uncov
lowlevel
asymptomat
viremia
may
role
bherpesvirus
human
human
caus
diseas
among
immunosuppress
patient
remain
unclear
prospect
studi
need
defin
effect
reactiv
infect
patient
hematolog
malign
virus
infect
individu
young
age
occasion
caus
selflimit
childhood
febril
ill
without
skin
rash
primari
infect
adult
rare
though
mononucleosislik
syndrom
caus
describ
case
report
among
hsct
recipi
also
associ
syndrom
pneumon
hepat
enceph
bone
marrow
suppress
well
asymptomat
viremia
unclear
signific
associ
mening
enceph
neurolog
dysfunct
possibl
role
bone
marrow
suppress
uncertain
diagnost
assay
evolv
unfortun
still
limit
differenti
activ
diseas
latent
viru
tabl
serolog
perform
use
varieti
assay
eia
radioimmunoassay
indirect
fluoresc
assay
adult
seroposit
pair
sera
show
rise
titer
consid
diagnost
igm
antibodi
may
limit
presenc
fals
posit
gener
popul
older
serolog
assay
also
limit
crossreact
test
wide
avail
littl
clinic
util
pcr
assay
perform
serum
plasma
whole
blood
csf
tissu
cellfre
sampl
serum
plasma
csf
may
better
differenti
activ
infect
presenc
latent
viru
immunohistochem
stain
tissu
sampl
also
limit
necessarili
separ
activ
latent
viru
pcr
antigen
stain
assay
found
much
clinic
util
date
frequent
unavail
routin
test
outsid
research
set
need
activ
antivir
therapi
particular
remain
unclear
ganciclovir
foscarnet
use
treatment
presum
infect
vitro
report
resist
ganciclovir
among
isol
report
prospect
studi
guid
manag
agent
yet
convinc
clinic
scenario
therapi
infect
warrant
vitro
foscarnet
ganciclovir
inhibit
replic
epstein
achong
barr
first
describ
infecti
agent
isol
cell
burkitt
lymphoma
relationship
ebv
heterophileposit
infecti
mononucleosi
wellestablish
relationship
ebv
malign
burkitt
lymphoma
nasopharyng
carcinoma
posttranspl
lymphoprolif
disord
ptld
hodgkin
diseas
other
area
activ
investig
seropreval
studi
indic
ebv
infect
present
greater
adult
popul
primari
infect
ebv
childhood
often
asymptomat
adolesc
adulthood
frequent
result
infecti
mononucleosi
caus
fever
lymphadenopathi
pharyng
virtual
everi
organ
system
may
affect
activ
ebv
infect
role
ebv
pathogenesi
malign
lymphoprolif
disord
particularli
challeng
patient
hematolog
disord
tabl
set
infecti
mononucleosi
divers
complic
report
includ
classic
associ
splenic
ruptur
hematolog
dysfunct
hemolyt
anemia
thrombocytopenia
dissemin
intravascular
coagul
report
oral
hairi
leukoplakia
uncommon
benign
lesion
frequent
associ
human
immunodefici
viru
hiv
infect
although
report
set
hsct
except
rare
develop
posttranspl
lymphoprolif
disord
ptld
often
encount
fear
complic
ebv
infect
hsct
risk
greatest
among
ebvseroneg
prior
transplant
infecti
mononucleosi
clinic
diagnosi
immunocompet
patient
right
clinic
set
support
evid
form
atyp
lymphocyt
seen
peripher
blood
smear
presenc
heterophil
antibodi
sometim
employ
immunocompromis
individu
serolog
may
detect
particularli
acut
infect
myriad
complic
ebv
infect
patient
popul
atyp
present
made
use
molecular
diagnost
essenti
diagnosi
manag
activ
ebv
infect
tabl
serolog
assay
heterophil
antibodi
antivir
capsid
antigen
igm
igg
earli
antigen
igg
nuclear
antigen
igg
perform
independ
indirect
immunofluoresc
eia
combin
simultan
multiplex
bead
assay
serolog
assay
transvers
myeliti
back
pain
sensori
loss
areflexia
ataxia
difficulti
bowel
bladder
function
optic
neuriti
visual
loss
possibl
combin
neurolog
deficit
pneumon
lymphocyt
interstiti
pneumon
commonli
pediatr
hivaid
myocard
congest
heart
failur
nephriti
report
tubulointerstiti
nephriti
membran
nephropathi
glomerulonephr
diffus
morbilliform
rash
associ
administr
penicillin
set
primari
infect
littl
valu
diagnos
acut
infect
immunocompromis
host
humor
respons
may
delay
absent
often
lag
develop
antivir
capsid
antinuclear
antigen
igg
antivir
capsid
antigen
igm
antiearli
antigen
igg
may
fail
appear
altogeth
quantit
pcr
assay
differ
laboratori
singl
assay
individu
use
patient
manag
agreement
signific
quantit
valu
within
individu
studi
hsct
recipi
copiesml
use
assess
risk
develop
ptld
situ
hybrid
biopsi
sampl
use
abund
small
ebvencod
rna
eber
oligonucleotid
becom
standard
detect
ebv
lymphoprolif
disord
malign
absenc
sever
complic
usual
indic
therapi
support
care
primari
infect
ebv
immunocompet
individu
use
corticosteroid
reduc
tonsillar
swell
airway
compromis
sometim
necessari
steroid
antivir
therapi
may
employ
lifethreaten
complic
hepat
possibl
liver
failur
hematolog
crise
includ
aplast
anemia
hemolysi
though
prospect
studi
support
use
immunocompromis
individu
therapeut
modal
divers
frequent
indic
either
prevent
treat
lymphoprolif
complic
risk
malign
ebv
acyclovir
ganciclovir
vitro
activ
lytic
replic
ebv
ganciclovir
slightli
greater
efficaci
howev
data
suggest
antivir
signific
effect
outcom
infect
ebvrel
lymphoprolif
disord
malign
immunocompromis
host
thought
depend
latent
infect
reli
cellular
enzym
ebv
episom
dna
synthesi
thu
inhibit
routin
antiherpesviru
nucleosid
analogu
acyclovir
ganciclovir
use
prophylaxi
patient
solid
organ
transplant
metaanalys
suggest
benefit
univers
prophylaxi
cmv
prevent
ptld
howev
firm
conclus
drawn
small
size
heterogen
patient
popul
nonrandom
natur
studi
induct
ebv
thymidin
kinas
gene
use
compound
arginin
butyr
attempt
order
induc
suscept
antivir
therapi
mix
degre
success
anoth
antivir
investig
vitro
assay
case
report
highdos
zidovudin
azt
maribavir
newer
compound
investig
use
treat
cmv
also
vitro
activ
ebv
differ
mechan
action
nucleosid
analogu
yet
trial
investig
use
ebv
infect
ptld
establish
therapeut
approach
includ
reduct
immunosuppress
degre
possibl
surgeri
isol
lesion
tradit
chemotherapi
radiat
especi
cn
lesion
use
rituximab
monoclon
antibodi
direct
toward
antigen
frequent
found
b
cell
main
site
ebv
infect
latenc
use
antivir
therapi
establish
diseas
may
use
reduc
activ
viral
replic
result
immunosuppress
appear
directli
impact
tumor
progress
solid
organ
transplant
recipi
cmv
cofactor
ptld
prevent
treatment
cmv
may
benefit
use
rituximab
preemptiv
approach
hsct
prevent
ptld
patient
otherwis
asymptomat
persist
ebv
viremia
alway
yield
persist
control
mani
patient
investig
approach
includ
infus
ebvprim
autolog
allogen
cytotox
tcell
anticytokin
therapi
recent
discov
member
herpesviru
famili
isol
patient
kaposi
sarcoma
coinfect
due
hiv
recogn
cofactor
kaposi
sarcoma
develop
varieti
lymphoprolif
malign
disord
viru
endem
mediterranean
region
central
southern
africa
much
south
america
although
rout
transmiss
remain
unclear
may
vari
depend
popul
analyz
endem
area
preval
increas
year
age
consist
transmiss
famili
member
close
contact
lowseropreval
area
unit
state
infect
highest
among
men
sex
men
suggest
possibl
sexual
transmiss
increas
number
sexual
partner
hiv
coinfect
also
increas
risk
though
heterosexu
transmiss
risk
hivrisk
group
inject
drug
user
appear
much
lower
among
patient
underli
hematolog
disord
suggest
infect
may
higher
compar
gener
popul
primari
infect
among
immunocompet
children
associ
mononucleosislik
syndrom
adult
milder
ill
frequent
asymptomat
immunocompromis
patient
primari
infect
associ
wide
array
clinic
present
includ
mononucleosi
patient
nonhodgkin
lymphoma
autolog
hsct
bone
marrow
suppress
renal
transplant
autolog
hsct
hemophagocyt
syndrom
patient
renal
transplant
other
hiv
infect
one
report
infant
digeorg
syndrom
dissemin
diseas
hepat
enterocol
pneumon
diseas
associ
latent
reactiv
infect
includ
kaposi
sarcoma
also
primari
effus
lymphoma
multicentr
castleman
diseas
kaposi
sarcoma
mesenchym
neoplasia
blood
lymphat
vessel
vari
present
outcom
differ
patient
popul
castleman
diseas
lymphoprolif
disord
lead
plasmablast
lymphoma
possibl
associ
well
valid
includ
multipl
myeloma
germinotrop
lymphoprolif
disord
well
nonlymphoid
malign
cardiovascular
diseas
pemphigu
vulgari
autoimmun
disord
sarcoidosi
current
diagnost
may
avail
mani
clinic
center
optim
use
assay
unclear
lack
gold
standard
test
inabl
assess
individu
risk
infect
among
differ
patient
popul
particular
ignor
natur
histori
barrier
proper
manag
among
avail
assay
tabl
pcr
commonli
use
antibodi
measur
variou
techniqu
includ
eia
immunofluoresc
western
blot
sensit
specif
vari
among
test
although
eia
technic
easier
perform
use
largescal
seropreval
studi
pcr
whole
blood
well
studi
may
offer
valu
diagnos
patient
kaposi
sarcoma
malign
infect
pcr
assay
vari
wide
term
sensit
specif
diagnos
primari
infect
sensit
closer
detect
tissu
sampl
kaposi
sarcoma
lesion
antivir
therapi
acyclovir
ganciclovir
foscarnet
cidofovir
appear
activ
viral
replic
vitro
acyclovir
may
less
activ
compar
other
ebv
antivir
therapi
alter
latent
gene
express
limit
clinic
valu
drug
case
report
antivir
therapi
gener
conclus
merit
establish
kaposi
sarcoma
lymphoprolif
disord
due
chemotherapi
radiotherapi
use
success
intralesion
inject
cidofovir
littl
effect
kaposi
sarcoma
compar
benefit
liposom
doxorubicin
though
recurr
resist
diseas
describ
latter
primari
effus
lymphoma
resist
tradit
chemotherapi
common
respons
rate
lower
therapi
target
latent
viral
gene
express
studi
activ
lytic
gene
express
make
viru
sensit
tradit
antivir
therapi
similar
ebv
also
investig
hydroxyurea
may
activ
latent
infect
cell
case
although
resist
develop
frequent
use
interferon
may
abl
trigger
cell
death
infect
cell
vitro
undergon
clinic
evalu
hiv
infect
immun
reconstitut
use
highli
activ
antiretrovir
therapi
haart
salutatori
effect
treatment
prevent
kaposi
sarcoma
immun
reconstitut
decreas
immunosuppress
may
also
benefit
patient
diseas
posttranspl
virus
primarili
affect
respiratori
tract
includ
closelyand
closelyrel
virus
adenoviru
influenza
parainfluenza
respiratori
syncyti
viru
rsv
less
studi
less
clinic
signific
infect
rhinoviru
coronaviru
rel
newli
describ
metapneumoviru
includ
section
measl
mump
rubella
also
may
caus
respiratori
syndrom
virus
spread
commun
airborn
droplet
inhal
physic
contact
environment
fomit
ingest
easili
transmit
patient
hematolog
malign
infect
control
measur
vaccin
proper
hand
hygien
healthcar
worker
household
contact
crucial
compon
prevent
spread
infect
potenti
lethal
complic
immunocompromis
host
reduct
immun
suppress
immun
reconstitut
remain
key
success
outcom
immunocompromis
host
respiratori
virus
caus
sever
diseas
frequent
complic
immunocompromis
individu
true
incid
asymptomat
respiratori
viral
infect
unknown
atyp
present
often
go
unrecogn
although
infect
limit
upper
respiratori
tract
rare
fatal
higher
mortal
associ
lower
respiratori
tract
infect
particularli
allogen
hsct
recipi
adenoviru
doublestrand
dnabas
nonenvelop
viru
associ
divers
clinic
find
current
classif
viru
distinguish
total
distinct
serotyp
divid
six
subgroup
af
base
dna
homolog
infect
usual
acquir
inhal
respiratori
droplet
ingest
direct
contact
conjunctiva
infect
occur
yearround
particular
peak
season
note
militari
recruit
within
first
week
fall
basic
train
immunocompromis
host
high
risk
sever
diseas
dissemin
viru
lead
signific
morbid
mortal
case
fatal
rate
report
high
among
pediatr
young
adult
hsct
recipi
infect
adenoviru
result
upper
respiratori
tract
infect
usual
benign
selflimit
clinic
syndrom
common
particularli
immunocompromis
host
tabl
allogen
hsct
recipi
greatest
risk
infect
diseas
due
adenoviru
though
complic
report
patient
underli
hematolog
malign
risk
infect
among
hsctrecipi
report
high
respiratori
tract
common
locat
viru
isol
risk
complic
diseas
includ
gvhd
young
age
presenc
opportunist
infect
surprisingli
patient
heavili
immunosuppress
suffer
immunolog
infecti
complic
transplant
higher
risk
infect
diseas
due
adenoviru
mortal
strongli
associ
pneumonia
without
evid
dissemin
standard
culturebas
serolog
method
detect
adenoviru
infect
commonli
avail
may
limit
clinic
util
avail
newer
molecular
techniqu
diagnosi
activ
infect
may
offer
opportun
earlier
intervent
tabl
eia
assay
serolog
test
replac
older
test
like
sensit
diagnos
recent
infect
antibodi
howev
acut
convalesc
sera
test
requir
order
document
increas
time
serotypespecif
neutral
antibodi
assay
may
use
therapeut
decisionmak
cultur
perform
sampl
respiratori
tract
conjunctiva
stool
urin
csf
site
sampl
stool
urin
particular
need
interpret
caution
ongo
shed
asymptomat
immunocompromis
individu
nephriti
renal
failur
possibl
prodrom
fever
hematuria
flank
pain
hsct
hemorrhag
cystiti
fever
gross
hematuria
anemia
pain
meningoenceph
fever
headach
confus
report
children
adenoviru
outbreak
hsct
hematopoiet
stem
cell
transplant
limit
util
culturebas
diagnost
antigen
detect
assay
much
rapid
lag
sensit
test
use
conjunctiv
sampl
suggest
overal
sensit
though
rate
higher
taken
earlier
ill
among
respiratori
specimen
sensit
antigen
test
may
also
rel
low
compar
test
respiratori
viral
pathogen
specif
predict
valu
remain
close
howev
ultim
valu
test
like
depend
adequaci
sampl
taken
pcr
emerg
method
choic
detect
activ
adenovir
diseas
infect
site
although
studi
need
associ
viremia
endorgan
diseas
mortal
asymptomat
viremia
appear
common
gener
appreci
control
clinic
trial
regard
treatment
adenoviru
infect
date
limit
vitro
suscept
assay
uncontrol
clinic
report
tabl
exact
role
antivir
therapi
adenoviru
diseas
remain
unclear
reduct
immun
suppress
immun
reconstitut
import
feasibl
two
commonli
use
agent
cidofovir
ribavirin
signific
toxic
cidofovir
signific
nephrotox
ribavirin
bone
marrow
toxic
risk
anemia
teratogen
cidofovir
appear
activ
agent
adenoviru
vitro
clinic
experi
suggest
capac
reduc
viremia
viruria
subsequ
clinic
improv
patient
variou
serotyp
differ
respons
cidofovir
dose
length
therapi
remain
unclear
cidofovir
cidofovir
vitro
activ
serogroup
adenoviru
case
report
uncontrol
case
seri
suggest
clinic
effect
dli
donor
lymphocyt
infus
associ
clearanc
adenoviru
case
report
gastroenter
hsct
case
report
lifethreaten
hemorrhag
cystiti
hsct
ganciclovir
ganciclovir
may
vitro
activ
adenoviru
high
level
may
clinic
achiev
studi
hsct
patient
receiv
ganciclovir
cmv
prophylaxi
may
shown
protect
effect
ivig
combin
use
ivig
ribavirin
agent
report
least
two
case
ribavirin
vitro
ribavirin
mix
activ
adenoviru
case
report
mix
clinic
effect
largest
case
seri
show
associ
ribavirin
surviv
hsct
recipi
adenoviru
infect
vidarabin
vitro
activ
appear
margin
use
case
report
treatment
hemorrhag
cystiti
zalcitabin
ddc
ddc
vitro
activ
anim
model
adenoviru
infect
efficaci
prevent
pneumonia
dli
donor
lymphocyt
infus
hsct
hematopoiet
stem
cell
transplant
cmv
cytomegaloviru
ivig
intraven
immunoglobulin
dose
mgkg
given
iv
weekli
two
three
dose
follow
infus
everi
week
often
cite
cidofovir
usual
given
concomitantli
probenecid
help
prevent
renal
toxic
drug
hemorrhag
cystiti
may
relaps
immun
function
hydrat
urin
flow
essenti
compon
care
individu
despit
case
report
topic
administr
antivir
agent
proven
help
therapi
common
syndrom
spread
influenza
rsv
occur
outbreak
epidem
throughout
winter
parainfluenza
infect
occur
throughout
year
epidem
aris
occasion
fall
spring
three
spread
within
famili
household
contact
well
nosocomi
set
common
although
much
emphasi
place
influenza
rsv
singl
common
caus
lower
respiratori
tract
infect
children
rsv
parainfluenza
infect
like
underrecogn
elderli
immunocompromis
patient
popul
influenza
viru
b
capabl
invas
infect
patient
hematolog
malign
influenza
close
associ
chang
two
major
glycoprotein
hemagglutinin
h
neuraminidas
n
antigen
shift
glycoprotein
associ
epidem
worldwid
pandem
influenza
role
minor
chang
call
antigen
drift
close
associ
local
outbreak
influenza
b
lesser
propens
antigen
chang
parainfluenza
paramyxovirida
famili
divid
four
major
serotyp
parainfluenza
preval
serotyp
also
associ
strongli
develop
pneumonia
bronchiol
rsv
also
member
paramyxovirida
famili
two
subtyp
describ
b
present
simultan
commun
outbreak
though
subtyp
typic
caus
sever
diseas
influenza
parainfluenza
rsv
associ
prolong
clinic
cours
risk
pneumonia
coinfect
pathogen
death
patient
hematolog
malign
among
immunocompet
nonelderli
adult
influenza
parainfluenza
rsv
tend
selflimit
upper
respiratori
tract
ill
febril
syndrom
set
hematolog
malign
frequenc
lower
respiratori
tract
involv
increas
dramat
risk
dissemin
system
complic
tabl
cardiac
cn
involv
report
parainfluenza
complic
diagnosi
pulmonari
infiltr
infect
heart
failur
involv
lower
respiratori
tract
increas
risk
bacteri
fungal
superinfect
includ
streptococcu
pneumonia
staphylococcu
aureu
avail
molecular
assay
viral
antigen
detect
test
alter
clinic
approach
respiratori
viral
infect
viral
cultur
remain
necessari
suscept
test
viral
type
identif
new
pathogen
howev
laboratori
increasingli
util
rapid
test
method
identif
respiratori
virus
none
rapid
antigen
test
well
studi
immunocompromis
host
though
immunocompet
patient
like
sensit
specif
rang
adequaci
respiratori
specimen
provid
test
limit
factor
sensit
assay
may
also
limit
compar
newer
molecular
assay
tabl
rapid
diagnost
signific
implic
success
therapi
howev
therapi
virus
vari
term
efficaci
clinic
data
earli
diagnosi
earli
initi
antivir
therapi
influenza
like
rsv
import
delay
chemotherapi
hsct
patient
hematolog
malign
respiratori
viral
infect
may
improv
outcom
emphas
import
appropri
rapid
diagnosi
tabl
detect
rsvspecif
antigen
cell
surfac
taken
respiratori
sampl
use
immunofluoresc
antibodi
techniqu
rapid
wide
avail
sensit
may
vari
depend
patient
qualiti
sampl
pcr
rsvspecif
molecular
amplif
use
respiratori
specimen
sensit
specif
may
superior
antigen
detect
patient
hematolog
malign
oseltamivir
emerg
commonli
use
antivir
therapi
influenza
eas
administr
toler
neuraminidas
inhibitor
like
zanamivir
efficaci
influenza
b
usual
treatment
immunocompet
individu
day
immunocompromis
patient
particularli
hsct
recipi
patient
complic
diseas
prolong
therapi
may
warrant
data
specif
hsct
recipi
suggest
earli
therapi
use
oseltamivir
possibl
reduc
viral
shed
risk
pneumonia
adamantan
amantidin
rimantidin
classifi
inhibitor
efficaci
influenza
although
less
expens
neuraminidas
inhibitor
limit
increas
rate
resist
januari
center
diseas
control
cdc
issu
alert
avoid
use
inhibitor
influenza
season
unit
state
due
unaccept
high
rate
resist
seen
strain
circul
time
precaut
recommend
season
well
definit
suscept
test
establish
agent
also
use
prophylaxi
outbreak
though
dose
length
therapi
suscept
circul
strain
may
vari
immun
central
compon
influenza
control
use
annual
trival
inactiv
influenza
vaccin
among
hsct
recipi
healthcar
worker
household
contact
may
decreas
attack
rate
commun
nosocomi
set
vaccin
respons
gener
reduc
among
patient
hematolog
malign
hsct
potenti
benefit
prevent
far
outweigh
risk
incur
administ
vaccin
accordingli
annual
vaccin
recommend
patient
popul
newer
liveattenu
influenza
vaccin
mg
po
mg
po
qd
crcl
mlmin
sever
liver
diseas
dose
unclear
inhal
anecdot
effect
immunocompet
individu
oral
therapi
like
parainfluenza
ribavirin
dose
unclear
report
use
mgkgday
three
divid
dose
without
anoth
gday
inhal
therapi
report
hsct
recipi
rsv
ribavirin
dose
unclear
report
use
g
aerosol
three
time
daili
report
patient
hematolog
malign
hsct
palivizumab
mgkg
im
q
monthli
winter
season
novemb
april
prophylaxi
benefit
seen
therapi
rsv
respiratori
syncyti
viru
crcl
creatinin
clearanc
hsct
hematopoiet
stem
cell
transplant
im
intramuscularli
administ
intranas
approv
use
unit
state
individu
age
year
recommend
immunocompromis
individu
household
contact
risk
transmiss
parainfluenza
efficaci
therapi
less
clear
establish
proven
agent
ribavirin
oral
iv
aerosol
without
intraven
immunoglobulin
anecdot
efficaci
largest
studi
evalu
use
ribavirin
hsct
note
differ
mortal
viru
shed
particularli
treatment
rsv
appear
moder
effect
studi
use
inhal
ribavirin
proven
effect
immunocompet
children
data
suggest
efficaci
adult
hsct
popul
earli
diagnosi
intervent
may
key
improv
outcom
particular
group
replet
antibodi
hypogammaglobulinem
host
may
use
current
palivizumab
monoclon
antibodi
direct
toward
rsv
studi
prophylact
agent
children
risk
respiratori
complic
rsv
infect
trial
investig
use
therapeut
agent
combin
ribavirin
reportedli
ongo
welltoler
hsct
popul
success
treat
rsv
pneumon
combin
corticosteroid
case
report
women
relaps
hodgkin
diseas
autolog
hsct
human
metapneumoviru
hmpv
recent
describ
respiratori
viru
paramyxoviru
famili
hmpv
ubiquit
pathogen
account
substanti
portion
respiratori
tract
ill
normal
children
recent
studi
suggest
hmpv
unrecogn
pathogen
long
serolog
sampl
avail
hmpv
common
rsv
common
parainfluenza
propens
winter
month
mani
question
remain
regard
role
agent
immunocompromis
individu
mechan
spread
commun
prevent
therapi
hmpv
like
caus
upper
respiratori
tract
infect
well
bronchiol
pneumonia
infant
elderli
immunocompromis
individu
particularli
hsct
recipi
upper
respiratori
tract
prodrom
symptom
common
prior
onset
lower
respiratori
tract
diseas
death
result
lower
respiratori
tract
diseas
describ
set
hsct
may
rel
common
outcom
hmpv
pneumonia
pcr
viral
rna
establish
assay
diagnosi
test
respiratori
secret
tissu
biopsi
sampl
via
pcr
sensit
although
true
incid
asymptomat
viral
shed
remain
unclear
biopsi
lung
tissu
patient
pneumonia
presum
caus
hmpv
show
chang
consist
viral
pneumon
otherwis
nonspecif
chang
may
includ
diffus
alveolar
damag
mononuclear
cell
infiltr
definit
viral
inclus
although
clinic
data
guid
therapi
ribavirin
appear
vitro
activ
hmpv
equival
rsv
mous
model
hmpv
infect
suggest
ribavirin
may
efficaci
vivo
prospect
clinic
studi
need
respiratori
pathogen
includ
rhinovirus
coronavirus
measl
mump
rubella
rhinovirus
coronavirus
associ
common
cold
symptom
gener
selflimit
consist
upper
respiratori
tractrel
complaint
rhinorrhea
sinu
congest
pharyng
cough
although
virus
thought
limit
upper
respiratori
tract
replic
report
isol
lower
respiratori
tract
exist
outcom
infect
due
rhinovirus
coronavirus
patient
hematolog
malign
well
character
incid
sever
infect
due
rhinovirus
unknown
fatal
pneumonia
attribut
infect
rhinovirus
patient
undergon
hsct
use
reversetranscriptas
pcr
rtpcr
rhinovirus
coronavirus
bronchoalveolar
lavag
sampl
patient
undergon
hsct
suggest
isol
rhinovirus
lower
respiratori
tract
sampl
associ
coinfect
pathogen
eg
bacteria
fungi
virus
valid
rtpcr
respiratori
sampl
remain
unclear
laboratori
cultur
techniqu
pcr
avail
detect
virus
clinic
sampl
establish
antivir
therapi
infect
measl
mump
rubella
uncommon
pathogen
us
due
effect
vaccin
program
vaccin
live
attenu
viru
vaccin
involv
three
pathogen
live
viru
vaccin
gener
avoid
immunocompromis
individu
though
consid
safe
effect
children
acut
lymphoblast
leukemia
effect
treat
chemotherapi
sporad
case
three
virus
occur
measl
rubeola
typic
associ
cough
coryza
fever
maculopapular
rash
limit
data
measl
immunocompromis
patient
cumul
case
report
suggest
casefat
rate
among
oncolog
patient
high
complic
infect
includ
pneumon
enceph
may
common
typic
rash
measl
may
absent
immunocompromis
patient
complic
diagnosi
serolog
cultur
rtpcr
use
diagnos
measl
serolog
commonli
avail
acut
convalesc
sera
requir
demonstr
requisit
fourfold
increas
time
confirm
diagnosi
known
effect
treatment
measl
infect
establish
highdos
vitamin
use
children
report
decreas
sever
diseas
ribavirin
remain
unproven
benefit
mump
member
paramyxoviru
famili
commonli
associ
parot
though
clinic
manifest
divers
includ
mening
enceph
hear
loss
orchiti
oophor
myocard
arthriti
other
like
measl
mump
usual
rare
ill
though
larg
outbreak
unit
state
recent
character
januari
octob
total
case
confirm
probabl
mump
report
involv
total
state
case
came
iowa
kansa
wisconsin
illinoi
cluster
around
colleg
campus
natur
histori
ill
immunocompromis
individu
remain
unclear
diagnosi
usual
standard
serolog
method
eia
often
use
due
eas
perform
reliabl
therapi
entir
support
rubella
german
measl
member
togavirida
famili
although
often
associ
mild
innocu
infect
adult
children
congenit
acquisit
devast
effect
unborn
fetus
thank
broad
use
liveattenu
vaccin
rubella
longer
endem
unit
state
less
case
report
annual
among
foreignborn
person
enterovirus
heterogen
group
virus
along
rhinovirus
aphthovirus
cardiovirus
hepat
viru
make
picornavirida
famili
enterovirus
subclassifi
differ
group
total
serotyp
tabl
tend
peak
season
infect
temper
climat
summer
autumn
month
spread
gener
via
fecalor
rout
though
respiratori
transmiss
may
possibl
although
cellmedi
immun
gener
play
import
role
viral
immunolog
humor
immun
thought
particular
import
control
enterovir
infect
sever
outcom
note
patient
agammaglobulinemia
immunocompet
host
vast
major
enterovir
infect
produc
complet
asymptomat
infect
occasion
mild
febril
ill
without
upper
respiratori
tract
symptom
may
present
symptom
rarer
wellcharacter
tabl
patient
undergon
hsct
fatal
complic
document
occasion
virus
appear
precipit
gastrointestin
gvhd
case
protract
fatal
enterovir
infect
among
patient
sever
bcell
dysfunct
hereditari
form
agammaglobulinemia
particular
clinic
scenario
enteroviru
rna
sometim
persist
recov
month
year
multipl
anatom
site
csf
lung
myocardium
bone
marrow
hsct
combin
underli
tcell
dysfunct
combin
suppress
humor
respons
may
contribut
profound
infect
well
howev
true
incid
enterovir
infect
popul
remain
unclear
estim
incid
enterovir
infect
among
hsct
recipi
though
mortal
thought
low
overal
associ
coinfect
pathogen
clear
independ
risk
factor
infect
among
hsct
recipi
identifi
diagnosi
enterovir
infect
involv
use
serolog
cultur
pcr
tabl
mani
limit
two
method
pcr
becom
favor
approach
microneutr
serolog
assay
offer
benefit
serotypespecif
method
immunofluoresc
assay
eia
may
show
crossreact
serotyp
specif
measur
serotyp
also
hamper
clinic
util
test
differ
serotyp
known
routin
diagnosi
enterovirus
serolog
alway
realist
serolog
use
look
evid
polio
infect
cultur
laborintens
requir
multipl
cell
line
effect
excret
enterovirus
gastrointestin
tract
persist
infect
long
week
isol
viru
stool
rectal
swab
possibl
oropharynx
may
result
fals
posit
assay
hold
true
pcr
use
sampl
taken
anatom
locat
experi
pcr
come
csf
sampl
case
suspect
asept
mening
sensit
may
higher
cultur
much
clinic
use
establish
treatment
enterovirus
intraven
immunoglobulin
ivig
use
mix
success
variou
case
report
patient
persist
mening
children
myocard
compar
histor
control
antibodi
respons
enteroviru
serotypespecif
ivig
may
clinic
use
case
data
regard
dose
durat
use
ivig
previou
investig
specif
antivir
therapi
enterovirus
result
develop
compound
known
pleconaril
pleconaril
act
bind
viral
capsid
antigen
impair
viral
bind
uncoat
clinic
trial
variou
case
report
pleconaril
use
asept
mening
shown
modest
clinic
benefit
develop
put
hold
control
polio
via
vaccin
virtual
elimin
wild
polio
viral
infect
western
hemispher
loss
immun
polioviru
welldocu
patient
allogen
hsct
led
recommend
revaccin
inactiv
polioviru
vaccin
transplant
live
viru
vaccin
avoid
immunosuppress
patient
live
attenu
oral
polioviru
vaccin
longer
avail
unit
state
due
rare
sever
complic
vaccineassoci
paralyt
polio
sinc
implement
inactiv
vaccin
vaccineassoci
paralyt
polio
elimin
unit
state
viral
hepat
b
c
unrel
virus
capabl
induc
acut
acut
chronic
liver
diseas
hepat
b
viru
hbv
hepat
c
viru
hcv
particular
import
abil
establish
chronic
infect
reactiv
immunosuppress
hepat
member
picornavirida
famili
transmit
via
fecalor
rout
one
individu
anoth
though
infect
mild
fulmin
hepat
signific
mortal
report
howev
current
report
hepat
diseas
hsct
patient
make
true
risk
incid
infect
popul
unknown
transmiss
result
persontoperson
contact
sexual
contact
ingest
contamin
food
water
also
rare
report
transmiss
via
blood
product
ingest
viru
replic
gastrointestin
epithelium
produc
transient
viremia
lead
infect
replic
hepatocyt
averag
incub
period
close
week
symptom
infect
usual
includ
fever
malais
hepat
without
jaundic
differenti
diagnosi
includ
numer
infecti
noninfecti
etiolog
includ
virus
cmv
ebv
hsv
vzv
hepatitid
diagnosi
usual
made
via
measur
serum
antihepat
igm
antibodi
right
clinic
set
antibodi
usual
detect
week
ill
persist
immunocompet
individu
sever
month
detect
viral
rna
via
pcr
avail
research
set
treatment
support
avail
antivir
therapi
immun
globulin
specif
hepat
administ
intramuscularli
provid
shortterm
protect
though
longterm
prevent
ideal
use
vaccin
group
recommend
posthsct
seroneg
patient
live
travel
endem
area
receiv
inactiv
hepat
vaccin
hbv
along
hcv
abil
establish
chronic
infect
occasion
caus
fatal
posttranspl
hepat
hsct
recipi
despit
avail
effect
vaccin
hbv
continu
import
caus
morbid
mortal
unit
state
patient
higherpreval
area
southeast
asia
china
subsaharan
africa
greater
risk
exposur
viru
perinat
period
greater
risk
chronic
infect
subsequ
complic
incid
acut
hbv
unit
state
seem
declin
among
pediatr
patient
reflect
like
efficaci
implement
univers
vaccin
among
adult
acut
infect
continu
increas
among
hsct
recipi
preval
hbv
infect
unit
state
estim
common
risk
factor
infect
includ
histori
multipl
sex
partner
men
sex
men
inject
drug
use
asid
usual
inocul
intim
mucocutan
contact
perinat
infect
transfus
infect
blood
product
transplant
infect
organ
welldescrib
mode
transmiss
major
patient
acut
hbv
infect
asymptomat
despit
activ
viral
replic
elev
hepat
chemistri
incub
period
last
month
time
patient
may
experi
constitut
symptom
onethird
develop
icter
hepat
fulmin
hepat
hepat
failur
unusu
hbv
like
due
immunemedi
complic
rather
virallymedi
hepat
necrosi
risk
develop
chronic
infect
invers
relat
patient
age
perinat
infect
carri
highest
risk
chronic
infect
diagnos
persist
month
elev
hepat
chemistri
particularli
alanin
aminotransferas
alt
level
patient
chronic
diseas
asymptomat
unless
develop
cirrhosi
complic
thereof
immun
complexmedi
complic
outsid
liver
includ
membran
membranoprolif
glomerulonephr
well
polyarter
nodosa
diagnosi
hbv
usual
serolog
antigendetect
nucleic
acid
amplif
commonli
use
immunohistochem
stain
liver
biopsi
use
assess
hepat
injuri
viral
replic
tabl
hepat
b
surfac
antigen
test
primari
marker
identifi
acut
chronic
infect
detect
earli
day
infect
modern
autom
eia
test
occasion
patient
activ
infect
found
neg
hepat
b
surfac
antigen
assay
patient
usual
serolog
evid
hepat
b
core
antibodi
lowlevel
hbv
dna
level
phenomenon
common
patient
hbv
hiv
coinfect
develop
realtim
pcr
assay
creat
sensit
assay
avail
detect
hbv
hbv
dna
level
measur
pcr
directli
correl
risk
liver
diseas
death
drug
resist
patient
therapi
though
baselin
valu
may
vari
individu
individu
monitor
regular
basi
may
use
particularli
patient
therapi
although
differ
algorithm
exist
check
patient
hbv
viral
load
pcr
two
four
time
yearli
therapi
may
provid
assess
respons
failur
antivir
agent
achiev
log
decreas
viral
load
month
rebound
viral
replic
log
greater
initi
respons
often
consid
evid
failur
standard
quantif
intern
unit
iu
ml
enhanc
comparison
differ
molecular
assay
lamivudin
load
dose
mg
set
decreas
renal
function
often
given
first
day
start
lower
daili
dose
entacavir
dose
higher
end
rang
gener
reserv
lamivudinerefractori
diseas
agent
evalu
treatment
hbv
lessstudi
time
includ
emtricitibin
ftc
tenofovir
tdf
telbivudin
valtorcitabin
clevudin
tenofovir
emtricitibin
current
use
treatment
hiv
infect
shown
particular
promis
set
hiv
hbv
coinfect
although
studi
detail
hsct
recipi
popul
numer
case
report
exist
regard
efficaci
antivir
prophylact
agent
primari
therapeut
chronic
carrier
recipi
hbv
posit
donor
stem
cell
optim
length
therapi
yet
wellestablish
mani
agent
list
tabl
develop
resist
may
vari
individu
agent
implement
routin
univers
immun
protocol
effect
mean
prevent
spread
hbv
patient
undergo
allogen
hsct
hbv
immun
result
effect
antibodi
respons
though
system
reimmun
recipi
may
necessari
maintain
longterm
immun
acquisit
hcv
hsct
virtual
disappear
due
effect
test
donor
hcv
like
hbv
caus
acut
chronic
infect
acut
infect
frequent
asymptomat
hcv
lead
chronic
infect
patient
hsct
individu
acquir
hcv
increas
incid
chronic
infect
rapid
progress
cirrhosi
compar
otherwis
healthi
control
symptom
acut
infect
may
includ
malais
nausea
without
jaundic
chronic
hcv
infect
often
asymptomat
fluctuat
transaminas
level
patient
undergo
hsct
acquir
hcv
infect
rare
develop
sign
symptom
decompens
liver
diseas
first
year
transplant
beyond
mark
signific
portion
hsct
recipi
develop
cirrhosi
often
hepatocellular
carcinoma
hcv
diagnost
test
base
quantit
molecular
assay
though
serolog
assay
often
use
screen
secondgener
eia
test
wide
use
greater
sensit
firstgener
assay
thirdgener
eia
detect
addit
hcv
antigen
provid
advantag
highpreval
set
detect
acut
infect
seroconvers
previous
confirm
hcv
infect
set
posit
serolog
done
use
recombin
immunoblot
assay
immunoblot
techniqu
use
antigen
detect
secondgener
eia
increas
specif
posit
eia
reduc
fals
posit
result
lowpreval
set
patient
normal
hepat
chemistri
commonli
detect
hcv
rna
use
molecular
amplif
use
confirm
patient
manag
sinc
patient
acut
leukemia
hsct
may
less
like
develop
antibodi
respons
hcv
pcr
signific
advantag
diagnost
tool
variou
molecular
method
directli
compar
singl
quantit
assay
use
individu
commerci
avail
assay
includ
rtpcr
branch
chain
pcr
method
branch
chain
pcr
hcv
technic
easier
less
sensit
standard
rtpcr
techniqu
small
percentag
patient
chronic
infect
lowgrad
viremia
may
detect
pcr
assay
also
clinic
util
monitor
patient
therapi
success
virolog
respons
gener
defin
least
log
declin
baselin
level
week
therapi
wherea
patient
experi
declin
defin
nonrespond
erad
infect
sustain
virolog
respons
also
measur
use
pcr
assay
defin
undetect
viral
level
complet
therapi
month
later
patient
chronic
hcv
infect
hsct
consid
therapi
option
limit
current
combin
interferona
plu
ribavirin
poorli
toler
pegyl
interferon
may
better
toler
though
prolong
halflif
may
concern
patient
hematopoiet
toxic
interferon
may
instig
reactiv
gvhd
well
dose
regimen
depend
variabl
type
interferon
use
patient
toler
hcv
genotyp
ribavirin
typic
dose
mg
day
two
divid
dose
individu
kg
mg
day
two
divid
dose
kg
genotyp
mg
two
divid
dose
like
suffici
retrovirus
group
rna
virus
common
genet
profil
reproduct
machineri
use
viralspecif
enzym
revers
transcriptas
convert
rna
genom
integr
dna
sequenc
within
host
genom
clinic
signific
retrovirus
human
infect
includ
human
immunodefici
human
tcell
lymphotrop
virusi
ii
htlvi
ii
hiv
infect
increas
risk
nonhodgkin
lymphoma
diffus
larg
bcell
lymphoma
burkitt
lymphoma
two
common
form
primari
effus
lymphoma
ebvrel
polymorph
lymphoprolif
disord
also
well
describ
test
hiv
infect
via
eia
serolog
assay
blood
confirm
western
blot
quantit
molecular
assay
standard
thirdgener
eia
use
clinic
practic
util
recombin
dna
protein
immunodomin
region
detect
igm
igg
sensit
rang
specif
fals
neg
eia
test
may
occur
time
viral
transmiss
seroconvers
hypogammaglobulinemia
replac
transfus
infect
subtyp
infect
specificassay
use
posit
eia
confirm
western
blot
use
protein
deriv
three
major
genet
domain
retrovirus
gag
pol
env
possibl
explan
fals
posit
eia
assay
includ
hematolog
malign
autoimmun
disord
posit
rapid
plasma
reagin
rpr
test
infect
syphili
infect
specif
western
blot
use
vaccin
band
least
two
three
major
protein
identifi
test
score
posit
singl
band
identifi
test
frequent
interpret
indetermin
patient
latter
group
usual
true
posit
repres
crossreact
due
retrovirus
autoantibodi
heterophil
antibodi
vaccin
common
lab
error
rare
reflect
earli
primari
infect
prior
full
seroconvers
presenc
primari
infect
antibodi
hiv
usual
detect
averag
week
infect
occasion
delay
though
detect
circul
igg
month
quantifi
cellfre
hiv
rna
plasma
critic
part
assess
monitor
diseas
progress
respons
therapi
current
rtpcr
techniqu
detect
viral
load
low
copiesml
thought
shorten
window
period
hiv
detect
within
day
new
rapid
serolog
test
develop
order
increas
routin
test
cdc
recommend
posit
test
assay
confirm
usual
via
western
blot
htlvi
member
retroviru
famili
known
infect
mani
million
peopl
worldwid
htlvi
caus
adult
cell
leukemia
lymphoma
well
htlviassoci
myelopathi
tropic
spastic
paresi
htlvii
consist
link
signific
diseas
process
similar
hiv
tropism
cell
htlv
lead
cell
death
rather
promot
prolifer
transform
endem
japan
indonesia
middl
east
part
caribbean
south
america
africa
preval
rate
less
nonendem
area
unit
state
transmiss
thought
primarili
breastfeed
although
spread
via
blood
transfus
transplant
sexual
contact
factor
endem
area
diagnost
assay
htlv
similar
hiv
screen
primarili
carri
via
eia
assay
detect
circul
htlvspecif
antibodi
confirm
done
western
blot
analysi
western
blot
confirm
also
distinguish
htlvi
htlvii
pcr
test
avail
detect
provir
dna
whole
blood
treatment
htlv
infect
usual
indic
asymptomat
patient
set
adult
cell
leukemia
combin
zidovudin
nucleosid
revers
transcriptas
inhibitor
interferona
use
possibl
benefit
lymphoma
establish
use
nonhodgkin
lymphoma
chemotherapi
regimen
moder
success
allogen
hsct
also
report
two
polyomavirus
known
caus
infect
human
includ
jc
viru
bk
viru
small
nonenvelop
doublestrand
dna
virus
close
relat
papillomavirus
group
virus
papovavirida
famili
jc
bk
viru
first
isol
describ
jc
viru
caus
progress
multifoc
leucoencephalopathi
pml
demyelin
diseas
central
nervou
system
pml
best
describ
patient
acquir
immunodefici
syndrom
aid
though
rare
seen
solid
organ
hsct
recipi
immunosuppress
individu
includ
patient
hematolog
malign
individu
receiv
form
immunosuppress
antibodi
therapi
bk
viru
associ
nephropathi
ureter
stenosi
renal
transplant
recipi
hemorrhag
cystiti
hsct
recipi
jc
viru
infect
usual
acquir
childhood
associ
known
ill
acut
phase
adult
seroposit
pml
relat
reactiv
latent
viru
signific
period
immunosuppress
although
strongest
associ
aid
pml
origin
describ
set
lymphoprolif
disord
thought
low
preval
overal
among
patient
hematolog
malign
pml
present
subacut
neurolog
diseas
affect
multipl
system
depend
locat
cn
lesion
chang
patient
mental
statu
ataxia
motor
deficit
involv
one
extrem
describ
infect
oligodendrocyt
jc
viru
lead
demyelin
white
matter
subsequ
neurolog
consequ
diseas
progress
median
surviv
roughli
month
patient
aid
probabl
less
nonhiv
infect
patient
hematolog
malign
diagnosi
frequent
made
base
clinic
find
patient
hiv
infect
aid
compat
magnet
reson
imag
mri
scan
head
demonstr
one
white
matter
lesion
without
obviou
contrast
enhanc
mass
effect
suggest
diagnosi
comput
tomographi
ct
scan
tend
less
sensit
mri
scan
confirm
pml
activ
jc
viru
infect
made
use
brain
biopsi
jc
viru
molecular
test
csf
demyelin
intranuclear
inclus
seen
oligodendrocyt
typic
without
necrosi
inflamm
situ
hybrid
use
jc
viru
dna
probe
increas
sensit
specif
biopsi
find
test
circul
igg
antibodi
littl
diagnost
valu
due
ubiqu
infect
likewis
routin
csf
analysi
often
unhelp
may
may
reveal
chang
consist
activ
inflamm
elev
cell
count
protein
level
pcr
analysi
csf
jc
viru
dna
immunocompromis
patient
consist
clinic
histori
radiograph
find
often
use
make
diagnosi
csf
pcr
jc
viru
sensit
close
high
specif
brian
biopsi
may
need
face
neg
csf
pcr
confirm
diagnosi
therapi
signific
valu
treat
pml
revers
immun
defici
main
modal
therapi
cidofovir
limit
vitro
activ
jc
viru
shown
benefit
clinic
trial
patient
hiv
infect
pml
anoth
agent
cytarabin
vitro
activ
jc
viru
also
shown
benefit
compar
trial
patient
hiv
infect
pml
howev
noncompar
openlabel
studi
evalu
nonhiv
infect
individu
pml
found
cytarabin
dose
mgkg
iv
day
associ
stabil
neurolog
function
individu
aid
use
highli
activ
antiretrovir
therapi
haart
benefit
seri
bk
viru
infect
adult
estim
preval
infect
usual
acquir
childhood
tend
asymptomat
rout
transmiss
remain
unclear
though
respiratori
acquisit
postul
primari
infect
viru
remain
latent
urogenit
epithelium
well
lymphoid
tissu
circul
leukocyt
viral
reactiv
occur
period
immunosuppress
bk
viru
induc
vitro
transform
rodent
cell
often
human
cell
definit
evid
relationship
oncogenesi
human
proven
bk
viru
implic
caus
pneumonia
patient
aid
least
two
patient
underli
hematolog
malign
bk
viru
central
role
develop
bk
nephropathi
polyomaviru
nephropathi
pvan
ureter
stenosi
renal
transplant
recipi
postengraft
hemorrhag
cystiti
hsct
recipi
latter
syndrom
increasingli
recogn
often
patient
previous
thought
adenoviru
infect
symptom
rang
microscop
hematuria
pain
sever
hemorrhag
without
bladder
obstruct
symptom
persist
neutropen
immunocompromis
individu
though
numer
method
may
avail
diagnos
bk
viral
infect
tabl
urin
cytolog
molecular
assay
often
use
diagnost
tool
hemorrhag
cystiti
hsct
detect
bk
viruria
pcr
correl
activ
diseas
limit
somewhat
lack
specif
asymptomat
bk
viruria
document
nonren
solid
organ
transplant
recipi
elderli
patient
immunosuppress
hivinfect
patient
pregnant
women
otherwis
healthi
individu
bk
viruria
uncommon
gener
tend
lower
quantiti
hsct
recipi
hemorrhag
cystiti
hsct
patient
hemorrhag
cystiti
high
level
viruria
copiesml
level
copi
ml
correl
risk
hemorrhag
cystiti
patient
popul
pattern
bk
viruria
also
thought
potenti
signific
one
prospect
cohort
patient
went
develop
hemorrhag
cystiti
invari
experienc
peak
bk
viruria
measur
pcr
week
period
hsct
clinic
hemorrhag
cystiti
measur
plasma
pcr
presenc
bk
viru
may
also
show
correl
develop
hemorrhag
cystiti
level
greater
copiesml
strongli
correl
postengraft
hemorrhag
cystiti
casecontrol
studi
among
hsct
recipi
clinic
strategi
hemorrhag
cystiti
hsct
recipi
success
reduc
immunosuppress
use
relat
donor
reducedintens
condit
regimen
may
reduc
risk
posthsct
nonspecif
chang
possibl
seen
viral
infect
eg
adenoviru
malign
highli
sensit
screen
quantit
realtim
amplif
polyomavirusspecif
dna
sequenc
either
plasma
urin
highli
sensit
assay
limit
specif
see
text
realtim
assay
distinguish
jc
bk
viru
analysi
melt
curv
biopsi
situ
hybrid
viral
chang
uroepithelium
situ
hybrid
immunofluoresc
increas
sensit
specif
hemorrhag
cystiti
often
prevent
biopsi
often
thrombocytopenia
electron
microscopi
electron
microscopi
viral
particl
urin
sediment
biopsi
specimen
wide
avail
pcr
polymeras
chain
reaction
factor
may
contribut
risk
includ
chemotherapi
irradi
injuri
bladder
mucosa
thrombocytopenia
neutropenia
coinfect
adenoviru
cmv
reduct
bk
viruria
viremia
well
correl
reduc
incid
sever
hemorrhag
cystiti
vitro
suppress
bk
viral
replic
possibl
fluoroquinolon
antibiot
relat
compound
inhibit
dna
gyras
vitro
data
suggest
select
index
fluoroquinolon
inhibit
bk
viru
replic
low
clinic
signific
valu
welldesign
clinic
trial
need
valid
data
cidofovir
vitro
inhibitori
effect
bk
viru
use
case
report
system
bladder
instil
treat
bk
virusrel
hemorrhag
cystiti
use
bladder
instil
effect
patient
system
therapi
limit
renal
toxic
leflunomid
immunosuppress
agent
inhibit
cmv
hsv
bk
replic
vitro
use
treat
pvan
small
number
renal
transplant
recipi
combin
reduct
immunosuppress
studi
describ
use
hsct
recipi
hemorrhag
cystiti
